Known as a pioneering organisation with capabilities of design, development and manufacturing of a wide range of diagnostic medical devices, BPL Healthcare has one of the most comprehensive service and delivery systems in the country and an undisputed leadership in point-of-care segment.
Vijay Simha, COO & Vice-President, Healthcare Business Group, BPL in talks with eHEALTH.
Medical device is a complex multidisciplinary field and regulatory authorities are falling over each other in order to bring in a framework. Our current infrastructure and investment in public health system leaves much to be desired, and its time that both awareness and priority be assigned to this area
How have you seen the advancement in the field of medical electronics over last few decades? Which areas of healthcare have mostly been benefited through such technologies?
Seeing is believing seems to be the leitmotif of modern medical diagnosis. Imaging seems to have taken center stage and visualisation tools using Gamma Radiation, X-Rays, Ultrasound and Magnetic Resonance probes have made disease identification and location more precise.
However, very little progress has been made on the diagnosis and treatment of systemic diseases that may manifest itself as a cancer or an autoimmune response. Using molecular probes, the area of molecular diagnostics will begin to mature as a routine diagnostic tool over the next decade. Example of this can be the case of outbreak of infectious viral diseases like the H1N1 strain, not only in developing countries but also in highly developed nations and its control.
What is the current portfolio of electronic equipments, devices and solutions offered by BPL Healthcare? Which among them are currently your fast movers and majority revenue earners?
BPL focuses on diagnostic equipment that addresses the larger segment of the healthcare infrastructure; that is in the primary and secondary areas of practice. These tools help the medical practitioner obtain more precise and quick diagnosis of diseases. Sometimes, it’s a set of tools that need to work together to provide this effectiveness and efficiency. Our breadwinners are the point-of-care products.
What new initiatives and strategic advantages does BPL wish to derive out of its recent partnership with Welch Allyn? How do you foresee the partnership value-adding your top line and bottom line in short and long term?
Welch Allyn is a global major in the point of care devices area and BPL’s relationship stretches across these vast expanses of our geographies.The synergy is seen in the value that the customer would derive from this association. Both our companies are highly customer centric organisations.
What was the percentage growth and total turnover of BPL Healthcare in the last financial year?
This information is yet to be released officially.
What incentives and regulatory support do you wish from the government for boosting medical technology industry and making advanced healthcare affordable in the country?
I think the government should first remove the disincentives that exist. The ecosystem for development and manufacturing of medical devices is just not conducive for investors. Medical device is a complex multidisciplinary field and regulatory authorities are falling over each other in order to bring in a framework. Our current infrastructure and investment in public health system leaves much to be desired, and its time that both awareness and priority be assigned to this area. Disease screening and preventive healthcare programs could contribute largely to a healthy population.